Holen Sie sich die Stockscreener-App
114.39
0.09%
0.10
Handel nachbörslich:
114.39
Arcellx Inc Aktie (ACLX) Neueste Nachrichten
Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc.ACLX - Business Wire
Gilead Sciences to buy Arcellx in deal valued at $7.8 billion - MSN
Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise? - Yahoo Finance
Victory Capital Management Inc. Has $14.13 Million Stock Position in Arcellx, Inc. $ACLX - MarketBeat
Gilead’s US$7.8b Arcellx Deal Deepens Cell Therapy Diversification - simplywall.st
Gilead to Acquire Arcellx, Inc. (ACLX) for Up to $7.8 billion - Finviz
Are ACLX, DBRG, AVO, CVGW Obtaining Fair Deals for their Shareholders? - Sahm
Arcellx set to report earnings amid $7.8B Gilead deal - Investing.com
American Century Companies Inc. Has $33.82 Million Position in Arcellx, Inc. $ACLX - MarketBeat
Blue Owl Capital Holdings LP Buys Shares of 26,823 Arcellx, Inc. $ACLX - MarketBeat
(ACLX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Gilead Sciences stock forecast for 2030: Can $7.8B Arcellx deal push GILD to $220 with no patent cliff until 2036? - Traders Union
Arcellx, Inc. (NASDAQ:ACLX) Receives Average Rating of "Hold" from Analysts - MarketBeat
Halper Sadeh LLC is Investigating Whether ACLX, VRE, EHAB are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Halper Sadeh LLC is Investigating Whether ACLX, VRE, EHAB are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Top 2 Health Care Stocks That May Crash This QuarterArcellx (NASDAQ:ACLX), Anika Therapeutics (NASDAQ:ANIK) - Benzinga
Multiple Myeloma Market 2026: Gilead Sciences Acquires Arcellx for $7.8B to Control CAR-T Therapy - openPR.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arcellx Inc (ACLX), Alkermes (ALKS) and Progyny (PGNY) - The Globe and Mail
Arcellx Inc stock hits all-time high at 114.27 USD - Investing.com Australia
Are ACLX, VRE, LSF Obtaining Fair Deals for their Shareholders? - Stock Titan
Gilead Sciences’ Yeztugo Revenue Is Set to Jump 400%: Here’s What Comes Next - TIKR.com
Arcellx (NASDAQ:ACLX) Hits New 52-Week HighStill a Buy? - MarketBeat
Arcellx Inc stock hits all-time high at 114.27 USD By Investing.com - Investing.com UK
Arcellx, Inc. (ACLX) Stock Analysis: Navigating Biotech’s Cutting Edge with Strategic Alliances - DirectorsTalk Interviews
Cowen Downgrades Arcellx, Inc. (ACLX) to Hold on March 2, 2026 - Meyka
ACLX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Gilead Sciences Arcellx Deal Deepens Oncology Bet And Tests HIV Reliance - Yahoo Finance
Arcellx stock rating cut to Hold by TD Cowen on Gilead deal - Investing.com India
Arcellx President Sells $10 Million Worth of Shares After Acquisition Announcement - The Globe and Mail
Arcellx President Sells $10M Worth of Shares After Acquisition Announcement - The Globe and Mail
TD Cowen Downgrades Arcellx to Hold From Buy - marketscreener.com
Citigroup Inc. Sells 13,427 Shares of Arcellx, Inc. $ACLX - MarketBeat
TD Asset Management Inc Buys 129,248 Shares of Arcellx, Inc. $ACLX - MarketBeat
Vanguard Group Inc. Sells 37,798 Shares of Arcellx, Inc. $ACLX - MarketBeat
Insider Selling: Arcellx (NASDAQ:ACLX) Insider Sells 89,916 Shares of Stock - MarketBeat
Arcellx CEO Elghandour sells $10.2 million in ACLX stock - Investing.com
Tax-withholding sale by Arcellx (NASDAQ: ACLX) director Elghandour - Stock Titan
Arcellx, Inc. Hits Day High with 77.43% Surge in Stock Price - Markets Mojo
E-Trade Financial (NASDAQ: ACLX) files Form 144 listing 164,548 RSU shares - Stock Titan
Taxation With Representation: Linklaters, Wilson Sonsini - Law360
Gilead Sciences Inc Stock Moved Up by 3.72% on Feb 27: What Investors Need To Know - TradingKey
Arcellx, Inc. Experiences Evaluation Revision Amid Strong Market Performance and Volatility - Markets Mojo
Arcellx (NASDAQ:ACLX) Announces Earnings Results, Meets Estimates - MarketBeat
Arcellx, Inc. SEC 10-K Report - TradingView
Arcellx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
ACLX SEC FilingsARCELLX INC 10-K, 10-Q, 8-K Forms - Stock Titan
Guggenheim Downgrades Arcellx to Neutral From Buy, Adjusts PT to $115 From $120 - marketscreener.com
Arcellx, Inc. Opens with a 77.48% Gain, Outperforming S&P 500's 0.69% Increase - Markets Mojo
Guggenheim downgrades Arcellx stock rating on Gilead acquisition - Investing.com
Guggenheim downgrades Arcellx stock rating on Gilead acquisition By Investing.com - Investing.com Nigeria
Arcellx, Inc. Hits New 52-Week High of $114.26, Up 110% Yearly - Markets Mojo
Insider sells 19,675 shares — E-TRADE Financial (ACLX) files Form 144 - Stock Titan
Arcellx (ACLX) CFO reports tax-driven share sale after exercising 20,530 units - Stock Titan
Arcellx CFO Michelle Gilson Sells Shares to Cover Tax Obligations - TradingView
Is It Too Late To Consider Arcellx (ACLX) After Its Recent Share Price Surge? - Yahoo Finance
Arcellx set to report earnings amid pending Gilead acquisition By Investing.com - Investing.com South Africa
Arcellx set to report earnings amid pending Gilead acquisition - Investing.com
Gilead Snaps Up Arcellx For $115 Per ShareA $7.8 Billion Bet On Cancer Therapy - Bitget
Gilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy - Benzinga
Arcellx (NASDAQ:ACLX) Downgraded to Hold Rating by Evercore - MarketBeat
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):